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 ABSTRACT  
OBJECTIVE – The goal of this study was to examine whether metabolic abnormalities 
are responsible for the histological changes observed in Japanese patients with 
nonalcoholic fatty liver disease (NAFLD) who have undergone serial liver biopsies.   
RESEARCH DESIGN AND METHODS – In total, 39 patients had undergone 
consecutive liver biopsies. Changes in their clinical data were analyzed, and biopsy 
specimens were scored histologically for stage. 
RESULTS – The mean follow-up time was 3.0 years (range, 1.0–8.5 years). Liver 
fibrosis had improved in 12 patients (30.7%), progressed in 11 patients (28.2%), and 
remained unchanged in 16 patients (41%). Predictive variables for liver fibrosis 
progression included baseline aspartate aminotransferase activity and ∆A1C at 
follow-up (P=0.04 and 0.01, respectively). In a multiple regression analysis, only ∆A1C 
was an independent predictor of fibrosis progression in the liver (r = 1.23, P=0.04).   
CONCLUSIONS – Tight glycemic control is necessary to prevent histological 





 Accumulating trans-sectional evidence suggests that the presence of multiple metabolic 
disorders, including obesity, diabetes, dyslipidemia, hypertension, and ultimately 
metabolic syndrome, are associated with nonalcoholic fatty liver disease (NAFLD) (1). 
However, it remains unclear which metabolic abnormalities are responsible for the 
pathological progression of NAFLD, especially in Japanese patients, who generally are 
not severely obese compared with Western patients.  
We retrospectively compared clinical features with the histological changes in the 
livers of Japanese patients with NAFLD who had undergone serial liver biopsies.
 
RESEARCH DESIGN AND METHODS  
Subjects 
We recruited 195 patients with clinically suspected NAFLD who had undergone liver 
biopsies at Kanazawa University Hospital from 1997 through 2008. For details about the 
study subjects and the exclusion criteria, see Supplementary Figure 1. Of 178 patients 
diagnosed histologically as NAFLD, 39 had undergone serial liver biopsies.  
 
Data collection 
Clinical information, including age, gender, body measurements, and prevalence of 
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 metabolic abnormalities, was obtained for each patient. Venous blood samples drawn for 
laboratory testing before the liver biopsies were obtained. All subjects had been 
administered a 75-g oral glucose tolerance test at baseline and at follow-up.  
 
Liver biopsies 
Biopsies were obtained after a thorough clinical evaluation and receipt of signed 
informed consent from each patient. All biopsies were analyzed twice and at separate 
times randomly by a single pathologist who was blinded to the clinical information and 
the order in which the biopsies were obtained. The biopsied tissues were scored for 
steatosis, stage, and grade as described (2), according to the standard criteria for grading 
and staging of nonalcoholic steatohepatitis (NASH) proposed by Brunt et al. (3).  
For additional details on subjects, data collection methods, liver pathology, and 
statistical analyses, see Supplementary Methods. 
 
RESULTS  
The basal clinical and biochemical data from 39 patients with NAFLD are described in 
Supplementary Table 1. Prevalence of type 2 diabetes, hypertension, and dyslipidemia 
were 76, 35, and 64%, respectively. The mean follow-up period was 3.0 years (range, 
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 1.0–8.5 years). Medications for diabetes and medication changes during the follow-up 
period are described in Supplementary Table 2. Seventeen patients treated with oral 
diabetic agents were switched to insulin therapy after the initial biopsy. No patients 
initiated pioglitazone during follow-up. 
Liver fibrosis improved in 12 patients (30.7%), progressed in 11 patients (28.2%), and 
remained unchanged in 16 patients (41%). As shown in Table 1, fasting plasma glucose 
(FPG), A1C, insulin resistance indicators, and prevalence of metabolic disorders were 
not significantly different among the three liver fibrosis groups. Predictive values for the 
histological progression of the liver included the baseline aspartate aminotransferase 
activity and the change in A1C (∆A1C) between the initial and final liver biopsies 
(P=0.04 and 0.01, respectively). In a multiple regression analysis, ∆A1C was 
significantly associated with fibrosis progression (r = 1.23, P=0.04), although basal 
aspartate aminotransferase was not significant, as shown in Supplementary Table 3. In a 
logistic regression analysis, ∆A1C was significantly associated with fibrosis 
improvement (odds ratio, 0.47; P=0.03) after adjustments for age, gender, BMI, diabetes, 
hypertension, dyslipidemia, treatment with angiotensin II receptor blockers, insulin and 




In the present study, we showed that a change in glycemic control (∆A1C), but not 
changes in insulin resistance indicators, was an independent predictor of the progression 
of liver fibrosis in Japanese patients with NAFLD. This is the first report identifying a 
change in A1C as a predictor of the histological course in the liver of patients with 
NAFLD. Two of five previous longitudinal studies have identified obesity, higher BMI, 
and homeostasis model assessment of insulin resistance (HOMA-IR) as predictors of 
liver fibrosis progression in Western populations (4; 5). The difference between those 
results and the results of the present study may be due in part to differences in the 
assessed severity of obesity and insulin resistance between the populations. We 
previously demonstrated that diabetes is an independent risk factor for the progression 
of liver fibrosis in hepatitis C (6) and that diabetes accelerates the pathology of NASH in 
the type 2 diabetic rat model OLETF (7).  
Liver fibrosis is closely associated with two regulators of fibrosis: transforming growth 
factor-β (TGF-β) (8; 9) and plasminogen activator inhibitor type 1 (PAI-1) (8; 10). High 
glucose levels induce the expression of TGF-β (11) and PAI-1 (12). We previously 
reported that the expression of TGF family member genes, PAI-1, and genes involved in 
fibrogenesis are up-regulated in the livers of patients with type 2 diabetes (13; 14), 
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 suggesting that a diabetic state increases the risk for liver fibrosis.  
In the present study, only ∆A1C was associated with the progression of liver fibrosis, 
but not liver inflammation (data not shown). We speculate that the reduction of A1C 
inhibits the expression of master genes such as TGF-β and PAI-1 that are involved in the 
regulation of fibrogenesis, rather than genes involved in liver inflammation, and thereby 
improves liver fibrosis in NAFLD. 
The limitation of this study was small population size, and most of the study patients 
were diabetic. We could not evaluate the changes of liver histology according to the 
difference in detail characteristics such as treatment of diabetes. A large-scale 
prospective study is necessary to validate our results and to elucidate natural course of 
NAFLD.  
In conclusion, ∆A1C is an independent predictor for liver fibrosis progression in 
Japanese patients with NAFLD, and tight glycemic control is necessary to ameliorate 
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Table 1 – Basal and final clinical features and gradients of laboratory markers associated with changes in liver fibrosis in 39 patients with NAFLD  
  The basal data   The final data   
  Improved (n=12) Stable (n=16) 
Progressed 
(n=11)  P Improved (n=12) Stable (n=16) 
Progressed 
(n=11)  P 
simple fatty liver:NASH, n 3:9 9:7 10:1  10:2 9:7 6:5   
Age (years)  51.5 (29-66) 48.5 (20-79) 51.5 (29-66) 0.9     
Gender (M : F) 5 : 7 12 : 4 5 : 7 0.3     
BMI (kg/m2)  27.5 (23.2-34.1) 27.7 (22.5-44.4) 30.9 (23.4-37.7) 0.7 26.9 (22.8-31.2) 29.1 (24.3-44.8) 30.7 (24.1-36.3) 0.13 
AST (IU/L)  70 (11-106) 29 (14-86) 32 (13-83) 0.04 23 (11-28) 26 (15-71) 24 (14-164) 0.2 
ALT (IU/L)  71 (10-209) 48 (23-81) 40 (11-162) 0.1 21 (11-53) 36 (21-66) 31 (12-202) 0.1 
FPG (mg/dl) 133 (96-207) 143 (87-414) 111 (76-167) 0.1 103 (93-220) 121 (83-198) 116 (88-199) 0.5 
A1C (%)  8.2 (4.7-11.6) 8.0 (4.9-13.6) 6.2 (5.1-9.5) 0.2 6.0 (5.0-9.0) 6.2 (5.0-10.0) 7.0 (6.0-11.0) 0.1 
HOMA-IR 3.9 (0.7-5.5) 3.4 (1.9-7.7) 3.9 (1.6-11.1) 0.9 3.1 (1.5-8.5) 3.4 (1.9-7.7) 3.9 (1.6-11.1) 0.7 
QUICKI 0.32 (0.29-0.40) 0.31 (0.27-0.34) 0.31 (0.29-0.35) 0.5 0.33 (0.28-0.37) 0.32 (0.30-0.35) 0.31 (0.29-0.34) 0.5 
Muscle insulin resistance 2.1 (1.5-4.0) 1.7 (0.3-3.3) 3.0 (2.1-4.4) 0.5 2.0 (1.3-5.9) 2.4 (1.6-4.5) 1.9 (1.3-4.5) 0.3 
Hepatic insulin resistance (x106) 5.3 (2.3-10.2) 5.0 (2.3-10.0) 3.7 (1.4-10.6) 0.3 3.9 (1.4-9.8) 4.3 (1.9-15.9) 4.5 (2.3-8.8) 0.4 
Total cholesterol (mg/dl)  191 (128-276) 187 (129-252) 206 (163-244) 0.6 192 (114-224) 195 (136-273) 194 (162-234) 0.7 
TG (mg/dl)  111 (28-224) 114 (36-204) 96 (36-521) 0.7 104 (22-241) 115 (57-241) 131 (36-173) 0.6 
HDL – cholesterol (mg/dl)  47 (35-82) 51 (31-73) 48 (20-74) 0.7 53 (40-71) 52 (39-64) 52 (36-79) 0.9 
Platelets (x104/μl)  21.1 (9.4-30.8) 23.0 (7.0-38.2) 24.3 (20.2-41.2) 0.2 23.3 (14.5-27.6) 21.5 (6.3-31.8) 24.0 (15.2-32.6) 0.6 
Ferritin (μg/dl)  185 (13-452) 397 (190-604) 46 (10-347) 0.1 74 (16-211) 162 (110-614) 62 (10-171) 0.05 
hsCRP 0.40 (0.08-7.53) 0.14 (0.02-0.61) 0.06 (0.00-0.30) 0.2 0.09 (0.04-0.23) 0.10 (0.00-0.24) 0.09 (0.00-0.89) 0.8 
Type IV collagen 7S (ng/dl)  5.1 (2.7-10.0) 4.1 (3.1-7.2) 3.7 (3.3-4.5) 0.2 3.5 (2.3-3.9) 8.3 (3.2-14.0) 4.0 (3.2-5.0) 0.2 
HA (ng/dl)  20.6 (0.0-144.7) 25.5 (11.5-299) 30.4 (0.0-61.7) 0.8 32.8 (0.0-117.2) 24.5 (0.0-570) 24.3 (0.0-140.3) 0.6 
P-III-P (U/ml) 0.6 (0.5-1.2) 0.6 (0.4-45.0) 0.5 (0.4-0.6) 0.1 0.6 (0.3-0.8) 0.5 (0.5-233.0) 0.6 (0.4-1.0) 0.9 
Diabetes (%)  82 69 64 0.8 82  75  64  0.7 
Dyslipidemia (%)  73 63 73 0.7 73  63  73  0.7 
Hypertension (%)  64 18 36 0.2 64  18  36  0.2 
Metabolic syndrome (%)  73 38 27 0.3 67  50  45  0.5 
∆A1C     -1.9 (-6.0 - +0.4) -1.2 (-6.1 - +4.4) +0.3 (-1.8 - +7.1) 0.01 
∆BW     -4.7 (-10.6 - +10.2) +2.2 (-9.4 - +13.4) -0.9 (-12.7 - +9.6) 0.05 
∆ HOMA-IR         -1.3 (-4.4 - +1.2) -0.3 (-4.3 - +3.3) -0.7 (-6.1 - +1.8) 0.6 
Data are median (range) or %. BW, body weight; HA, hyaluronic acid. 
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Additional details on methods 
Subjects 
 We consecutively recruited 195 patients with clinically suspected NAFLD who had undergone 
liver biopsies at Kanazawa University Hospital from 1997 through 2008. Fatty liver was 
clinically diagnosed based on ultrasound examination showing an increase in hepatorenal 
contrast.  Hepatorenal contrast, also known as “bright liver” (1), is defined as the ratio of hepatic 
to kidney echo levels of over 1.0.  In each patient, all other liver disorders were excluded, 
including viral hepatitis B and C, primary biliary cirrhosis, autoimmune hepatitis, sclerosing 
cholangitis, hemochromatosis, Wilson’s disease, drug-induced liver injury, and biliary 
obstruction. All patients reported drinking less than 20 g/day of ethanol. Liver biopsies were 
performed during hospitalization.  Serum elevations in transaminase (>40 IU/L) were examined 
and metabolic disorders such as diabetes mellitus and obesity were treated. None of the patients 
were on medication (e.g., vitamin E or ursodeoxycholic acid), which could influence histological 
changes in the liver throughout the follow-up period.   
 
Data collection  
 1
 A diagnosis of diabetes mellitus was based on the American Diabetes Association criteria (2). 
Hypertension and dyslipidemia were defined according to metabolic syndrome definitions 
provided by the National Cholesterol Education Program–Adult Treatment Panel III (3).  
 Metabolic syndrome was defined as the presence of abdominal obesity (given as waist 
circumference: ≥85 cm for men, ≥90 cm for women) and included at least two of the following 
components: hypertriglyceridemia [≥150 mg/dl (≥1.69 mmol/l)] and/or low 
HDL-cholesterolemia [<40 mg/dl (<1.03 mmol/l)]; blood pressure (systolic ≥130 and/or diastolic 
≥85 mmHg), and fasting plasma glucose (FPG) [≥110 mg/dl (≥6.11 mmol/l)] according to the 
Japanese diagnostic criteria for metabolic syndrome (4). Laboratory tests included liver enzymes, 
blood counts, fasting lipid profile, A1C, glucose, insulin, high-sensitivity C-reactive protein 
(hs-CRP), ferritin, liver fibrosis markers such as type IV collagen domain 7S, hyaluronic acid, 
and procollagen III peptide (p-III-p) .  All tests were conducted and analyzed at the central 
clinical laboratory in our hospital. Insulin resistance indicators such as homeostasis model 
assessment of insulin resistance (HOMA-IR), quantitative insulin-sensitivity check index 
(QUICKI), and indices for muscle and hepatic insulin resistance were calculated based on the 
results of the 75-g oral glucose tolerance tests, using previously reported formulas: HOMA-IR = 
[fasting insulin (μU/ml) × fasting plasma glucose (μmol/l)]/22.5 (5), QUICKI = 1/[log (fasting 
insulin expressed in μU/ml) + log (fasting plasma glucose expressed in mg/dl)] (6). Index for 
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 muscle insulin resistance = 10,000/log [fasting glucose (mg/dl) × fasting insulin (μU/ml)] × 
[mean glucose (mg/dl) × mean insulin during the oral glucose tolerance test (μU/ml)], and Index 




Sections were cut from a paraffin block and stained with hematoxylin and eosin, and 
Azan–Mallory, and silver reticulin impregnation. The biopsied tissues were scored for steatosis 
(from 0 to 3), stage (from 1 to 4), and grade (from 1 to 3) as described (8), according to the 
standard criteria for grading and staging of NASH proposed by Brunt et al. (9). All cases showed 
variable degrees of steatosis that histologically corresponded to NAFLD. NASH was 
histologically diagnosed based on the presence of ballooned hepatocytes with lobular hepatitis. In 
contrast, livers without ballooned hepatocytes were diagnosed as fatty liver. The scoring system 
according to Brunt classification (9) applies to NASH, but not fatty liver. Therefore, for fatty liver 
without any features of steatohepatitis, we assigned a score of stage 0 and grade 0. In addition, 
when histological activity or fibrosis varied within a biopsy, cases were scored as an average (i.e., 
0.5 or 1.5) so that we could examine histological changes in detail.  
The progression of liver histology was defined as an increased stage score in the final biopsy with 
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 respect to the baseline; a decreased stage score was considered an improvement.   
 
Statistical analyses 
Continuous data are presented as the medians (ranges) and categorical data are presented as a 
number (%). A Kruskal–Wallis test and a χ2 test were applied for the analysis of differences in 
continuous and categorical variables.  The independent influence of significant variables on 
fibrosis progression was assessed using a multiple regression analysis. The odds ratio was 
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 Supplementary Figure 1 – Description of study subjects and exclusion criteria  
 
 
Died during follow-up (n=1)
Started hemodialysis (n=1) 
Interrupted hospital visit or changed hospital (n=70) 
Refused serial liver biopsies (n=67) 




Drug induced liver injury (n=1) 
CH(B) or CH(C) (n=3) 
Infectious mononucleosis (n=1) 
Non-NAFLD with only nuclear glycogen (n=10) 
Subjects with NAFLD 
at baseline 
178 subjects 




 Supplementary Table1 – Basal clinical and biochemical data of 39 patients with NAFLD  
normal range
Age (years) 47 (20-79)
Gender (M : F) 20 : 16
BMI (kg/m2) 27.8 (22.5-44.4) 18-25
AST (IU/L) 40 (11-106) 10-48
ALT (IU/L) 54 (10-209) 3-50
FPG (mg/dl) 128 (76-414) 70-110
HbA1c (%) 6.6 (4.7-13.6) 4.3-5.8
HOMA-IR 3.9 (0.7-11.1) <2.0
Total cholesterol (mg/dl) 199 (128-276) 132-220
TG (mg/dl) 112 (28-521) 32-150
HDL – cholesterol (mg/dl) 48 (20-82) 40-97
Platelets (x104/μl) 22.8 (7.1-41.2) 13-35
Ferritin (μg/dl) 185 (13-5-640) 6.2-138
hsCRP 0.17 (0-7.53) <0.2
Type IV collagen 7S (ng/dl) 4.1 (2.7-10.0) <6.0
HA (ng/dl) 24.7 (0-299) <50
P-III-P (U/ml) 0.6 (0.4-45.0) 0.3-0.8
Diabetes (%) 30 (76.9)
Dyslipidemia (%) 25 (64.1)
Hypertension (%) 14 (35.8)
Metabolic syndrome (%) 15 (38.4)  
Data are median (range) or numbers of patients; n=39; HA, hyaluronic acid. 
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 Supplementary Table2 – Changes of pathological score and the treatment for diabetes and 
hypertension in 39 patients with NAFLD  
Case Initial diagnosis Final diagnosis Stage Grade Steatosis DM Treatment for DM HT ARB 
Improved group
1 NASH FL  3 → 1  3 → 1  2 → 1 + diet → diet - -
2 FL FL  2 → 1  0 → 0  3 → 3 - - -
3 NASH FL  2 → 1  1 → 1  2 → 1 + diet → insulin + +
4 NASH FL  2 → 1  2 → 0  2 → 2 + diet → insulin - -
5 NASH FL  1 → 0.5  1 → 1  3 → 2 + SU → insulin - -
6 FL FL  2 → 1  0 → 0  2 → 1 + diet → insulin - -
7 NASH FL  3 → 1  2 → 0  2 → 1 + diet → diet + +
8 NASH NASH  1 → 0.5  2 → 1  2 → 2 + diet → insulin + +
9 NASH FL  3 → 2  2 → 1  3 → 2 - + -
10 NASH FL  3 → 2  2 → 0.5  3 → 2 + diet → diet - -
11 FL FL  1 → 0  0 → 0  1 → 1 + diet → insulin - -
12 NASH NASH  4 → 3  2 → 0.5  2 → 1 + diet → insulin + -
Progressed group
13 FL FL  1 → 2  0 → 0  1 → 1 + diet → insulin + +
14 FL NASH  1 → 3  0 → 2  3 → 3 　　+　→  IGT diet → diet - -
15 FL FL  1 → 2  0 → 1  1 → 1 + diet → diet + +
16 FL NASH  1 → 2  0 → 1  1 → 1 + α−GI → SU, Met + +
17 FL NASH  1 → 2  0 → 1  1 → 2 + diet → α-GI - -
18 FL FL  1 → 1.5  0 → 0.5  1 → 2 - - -
19 FL NASH  1 → 2  0 → 3  3 → 2 + diet → insulin + +
20 FL FL  1 → 2  0 → 0  1 → 2 + Met → Met, α-GI + -
21 FL FL  1 → 1.5  0 → 0.5  3 → 2 + diet → insulin + +
22 FL FL  1 → 1.5  0 → 0.5  2 → 2 - + -
23 NASH NASH  1 → 1.5  1 → 1.5  3 → 2 IGT diet → diet - -
Stable group
24 NASH NASH  3 → 3  3 → 3  1 → 1 + Met, SU → Met, SU - -
25 FL FL  1 → 1  0 → 0  2 → 1 + α−GI → insulin + +
26 FL FL  1 → 1  0 → 0  2 → 1 + diet → diet - -
27 FL FL  1 → 1  0 → 0  2 → 1 + Met, SU → insulin - -
28 FL FL  1 → 1  0 → 0  1 → 1 + diet → insulin + +
29 FL FL  1 → 1  0 → 0  2 → 1 - → IGT diet - -
30 FL FL  1 → 1  0 → 0  1 → 2 - → IGT diet - -
31 NASH NASH 4 → 4  2 → 2  2 → 1 + diet → insulin - -
32 FL FL  1 → 1  0 → 0  3 → 3 + diet → insulin - -
33 FL FL  1 → 1  0 → 0  2 → 3 + diet → diet + -
34 NASH NASH  1 → 1  1 → 1  1 → 1 + SU,　Pio → insulin - -
35 NASH NASH  1 → 1  1 → 1  3 → 3 + diet → diet - -
36 FL FL  2 → 2  0 → 0  3 → 3 + diet → diet - -
37 NASH NASH  2 → 2  1 → 1  2 → 2 + diet → insulin - -
38 NASH NASH 4 → 4  3 → 3  1 → 1 IGT diet → diet - -
39 NASH NASH 4 → 4  3 → 2  3 → 1 - → DM diet - -
Patients with histological improvement (Cases 1–12), progression (Cases 13–23), or stability 
(Cases 24–39) are indicated in the Improved, Progressed, and Stable groups, respectively.  
Presence of diabetes and hypertension, and the treatment with ARB are indicated by +.  
α-GI, α-glucosidase inhibitor; ARB, angiotensin II receptor blocker; FL, fatty liver; IGT, 
impaired glucose torelance; Met, metformin; NASH, nonalcoholic steatohepatitis; Pio, 
pioglitazone; SU, sulfonylurea. 
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 Supplementary Table3 –A multivariate analysis of the association between fibrosis 
progression and independent predictors  
variable r t -statistic p
the gradient of HbA1c 1.23 2.48 0.04
AST (at baseline) -9.79 -2.14 0.08  
Variables were adjusted by age, gender, and BMI. 
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 Supplementary Table4 –A logistic regression analysis of factors associated with 
liver fibrosis improvement  
Factor Odds ratio 95% CI p
Age (years) 1.01 0.91-1.13 0.75
Gender （male) 2.66 0.18-38.5 0.47
BMI (kg/m2) 0.92 0.63-1.35 0.69
Diabetes 0.23 0.00-16.4 0.5
Hypertension 18.2 0.58-566.8 0.09
Dyslipidemia 0.5 0.04-5.74 0.57
Observation period (years) 1.02 0.97-1.07 0.38
Treatment with ARB 0.4 0.00-69.5 0.73
Insulin 0.52 0.00-50.0 0.78
∆A1c 0.47 0.21-1.01 0.04
Multivariate model is adjusted for all variables for the model.  
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